5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Recruiting · NCT05452772 · Registry updated 2026-06-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder | Chemically-Induced Disorders, nicotine dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-06-29 | NCT05452772 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Johns Hopkins University | 579 |
| National Institute on Drug Abuse (NIDA) | 549 |
| New York University | 90 |
| University of Alabama at Birmingham | 467 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins University School of Medicine | Baltimore | United States | 7 |
| New York University | New York | United States | 26 |
| University of Alabama at Birmingham | Birmingham | United States | 247 |